The FDA has approved pembrolizumab for adults and children with classical Hodgkin lymphoma whose disease is refractory to or has relapsed after at least three prior therapies. The approval marks the first time that a PD-1 inhibitor has been indicated for blood cancers—and for children.
from Cancer via ola Kala on Inoreader http://ift.tt/2plLzds
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου